

Phase I, First-in-man Clinical Trial of `Dual' AR antagonist/Immune modulator (R)-9b in CRPC patients (PHAROS)

Nupam P. Mahajan^{*#}, Kiran Mahajan[#] and Douglas McNeel[®]

[#]Department of Surgery, Washington University, St. Louis; and [®]Department of Medicine, University of Wisconsin

^{*}Author for correspondence

Background: Prostate cancer (PC) is one of the leading cause of cancer deaths among American men. Advanced PC patients often receive androgen deprivation therapy, but, the recalcitrant disease recurs within 2-3 years, referred to as the Castration Resistant Prostate Cancer (CRPC). Androgen Receptor (AR) antagonists such as enzalutamide (Enz) or abiraterone (Abi) are currently favored therapeutics for PC patients, however, virtually all patients develop resistance. Post-CRPC state, therapeutic options for the recurrent disease are limited.

Methods: We discovered a non-receptor tyrosine kinase, ACK1, as a novel epigenetic modifier in prostate tumors, regulating AR/AR-V7 expression. Enthused with these data, we developed a new class of ACK1 small molecule kinase inhibitor, (R)-9b

Results: (R)-9b inhibits ACK1 and downregulates AR and prostate specific antigen (PSA) expression to suppress prostate xenograft tumor growth. Moreover, in immune competent mouse models, (R)-9b induces significant CD4⁺ and CD8⁺ T cell activation against syngeneic prostate tumors. Employing ex vivo 3-D assays, we confirmed that (R)-9b functionally reinvigorates peripheral blood mononuclear cells (PBMCs) of the CRPC patients to mount a robust immune response against human CRPC organoids. Together, these data indicated that ACK1 inhibitor, (R)-9b with tumor-intrinsic and tumor-extrinsic activities in the host tumor microenvironments is a novel class of inhibitor with much needed immunomodulatory activity. IND have been obtained from FDA (IND#167907). The phase I clinical trial for heavily pretreated CRPC patients has started. ([Clinicaltrials.gov/study/NCT06705686](https://clinicaltrials.gov/study/NCT06705686); acronym: PHAROS).

Conclusion: Patients were administered with dose of 60 mg/day, orally. So far, no adverse toxicity and multiple markers for early response are very favorable. To our knowledge, it is the first such compound to be tested in the human trial.

Conflict of Interest: `Inhibitors of ACK1/TNK2 Tyrosine Kinase', (patent no. 9,850,216 and 10,017,478) covers the (R)-9b molecule. N.P.M. and K.M are named as inventor of these patents, licensed by TechnoGenesys, Inc., N.P.M. and K.M are co-founders of TechnoGenesys, Inc., own stocks, and serve as consultants.

Funding Acknowledgements: N.P.M. is supported by NIH/NCI grants (R01CA273054, R01CA285526, R01CA276502, and R01CA286443).